Head to Head Survey: Newron Pharmaceuticals (OTCMKTS:NWPHF) & AEON Biopharma (NASDAQ:AEON)

AEON Biopharma (NASDAQ:AEON) and Newron Pharmaceuticals (OTCMKTS:NWPHF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 23.5% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares AEON Biopharma and Newron Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	$0.18	3.23
Newron Pharmaceuticals	$6.82 million	24.50	-$17.63 million	N/A	N/A

Newron Pharmaceuticals has higher revenue and earnings than AEON Biopharma.

Profitability

This table compares AEON Biopharma and Newron Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Newron Pharmaceuticals	N/A	N/A	N/A

Volatility & Risk

AEON Biopharma has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Newron Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AEON Biopharma and Newron Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
Newron Pharmaceuticals	0	0	0	0	0.00

AEON Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 759.25%. Given AEON Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than Newron Pharmaceuticals.

Summary

AEON Biopharma beats Newron Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.